<DOC>
	<DOC>NCT01482390</DOC>
	<brief_summary>This randomized, double-blind, multi-center, parallel-group study will evaluate the sustained virologic response and the safety of mericitabine (RO5024048) in combination with telaprevir and Pegasys/Copegus in patients with chronic hepatitis C infection. The anticipated time on study treatment is up to 48 weeks.</brief_summary>
	<brief_title>A Study of Mericitabine in Combination With Telaprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patients, &gt;/=18 years of age Chronic hepatitis C infection for at least 6 months duration Hepatitis C genotype 1a or 1b Patients must have discontinued prior hepatitis C treatment at least 12 weeks prior to enrollment in this study Patients showed a previous null response to therapy as defined by &lt; 2 log10 IU/ml decrease in viral titer after at least 12 weeks of treatment with Peginterferon/ribavirin (PEGIFN/RBV) Hepatitis C infection with a genotype other than genotype 1a or 1b Body mass index &lt;18 or &gt;/=36 Hepatitis A, hepatitis B, or HIV infection Herbal remedies &lt;/=1 month prior to the first dose of study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>